Abstract | BACKGROUND: METHODS: The protocol of this study was registered with PROSPERO (CRD42021227281). By using a network meta-analysis approach, the different treatments were compared and ranked based on their effectiveness and rates of irAEs at the different grades. Risk rates were determined through direct meta-analysis and indirect treatment comparison. RESULTS: 12 randomized clinical trials were included with a total of 7155 NSCLC patients. Network meta-analysis generated 15 comparisons. The combination treatment of I+C+D showed a longer progression-free survival and overall survival, while I+C was less toxic, and the toxicity of I+C+D or that of I+C had been significantly decreased, compared to that of monotherapy with either drug. According to the ranking analysis, I+C+D is consistently proved to be the most effective therapeutic strategy, while I+C is linked to the lowest rate of irAEs, with the rate of grade value of ≥3 irAEs. CONCLUSION: The combination treatment of I+C+D is the most effective approach for the first-line treatment of NSCLC patients treated with I+C, I, or C.
|
Authors | Yanwei Li, Feng He, Shuang Liu, Yu Zhang, Ling Li, Bin Wang, Lan Lan, Zhanyu Pan |
Journal | American journal of clinical and experimental immunology
(Am J Clin Exp Immunol)
Vol. 10
Issue 4
Pg. 93-102
( 2021)
ISSN: 2164-7712 [Print] United States |
PMID | 35106186
(Publication Type: Journal Article, Review)
|
Copyright | AJCEI Copyright © 2021. |